V900323
羟基脲
Vetec™, reagent grade, ≥98%
别名:
羟基尿素
登录 查看组织和合同定价。
选择尺寸
关于此项目
线性分子式:
NH2CONHOH
化学文摘社编号:
分子量:
76.05
EC Number:
204-821-7
UNSPSC Code:
12352200
PubChem Substance ID:
Beilstein/REAXYS Number:
1741548
MDL number:
产品名称
羟基脲, Vetec™, reagent grade, ≥98%
InChI key
VSNHCAURESNICA-UHFFFAOYSA-N
InChI
1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
SMILES string
NC(=O)NO
grade
reagent grade
product line
Vetec™
assay
≥98%
storage temp.
2-8°C
Gene Information
human ... RRM1(6240), RRM2(6241), RRM2B(50484)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
抗肿瘤剂。通过形成自由基硝基氧灭活核糖核苷还原酶，自由基硝基氧可结合到酶活性位点的酪氨酰自由基。这可阻断脱氧核苷酸的合成，从而抑制 DNA 合成，并且诱导细胞周期同步化或 S-期细胞死亡。
Legal Information
Vetec is a trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
hcodes
Hazard Classifications
Muta. 1B - Repr. 2
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Winfred C Wang et al.
Pediatrics, 132(4), 677-683 (2013-09-04)
In the BABY HUG trial, young children with sickle cell anemia randomized to receive hydroxyurea had fewer episodes of pain, hospitalization, and transfusions. With anticipated broader use of hydroxyurea in this population, we sought to estimate medical costs of care
Deepa Manwani et al.
Blood, 122(24), 3892-3898 (2013-09-21)
Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the fetal hemoglobin-reactivating agent hydroxyurea are currently the mainstay of treatment. Discoveries over the past 2 decades have highlighted
Guido Finazzi et al.
British journal of haematology, 161(5), 688-694 (2013-04-12)
Givinostat, a histone-deacetylase inhibitor (HDACi), inhibits proliferation of cells bearing the JAK2 V617F mutation and has shown significant activity with good tolerability in patients with chronic myeloproliferative neoplasms (MPN). In this multicentre, open-label, phase II study, 44 patients with polycythaemia
Suchitra Natarajan et al.
Neoplasia (New York, N.Y.), 15(3), 263-280 (2013-03-13)
The non-histone chromatin binding protein high mobility group AT-hook 2 (HMGA2) is expressed in stem cells and many cancer cells, including tumor initiating cells, but not translated in normal human somatic cells. The presence of HMGA2 is correlated with advanced
A Tefferi et al.
Leukemia, 28(12), 2300-2303 (2014-05-06)
The impact of calreticulin (CALR) mutations on long-term survival in essential thrombocythemia (ET) was examined in 299 patients whose diagnosis predated 2006. Mutational frequencies were 53% for Janus kinase 2 (JAK2), 32% for CALR and 3% for MPL; the remaining
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持